Search

for
Search:

Community Join

5 / 201 results

community Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China

90 upvotes 3 years ago

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA

13 upvotes 3 years ago

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

community Kintor Pharmaceutical’s KX-826 Shows Promising Results in Hair Loss Study

17 upvotes 1 year ago

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.

community New Hair Loss Treatment from Kintor Just Hit the Market: KX-826!

36 upvotes 2 years ago

Kintor Pharmaceutical's new hair loss treatment, KX-826, is entering the market. Users are eager to see its effectiveness before celebrating.

community Anyone found Clascoterone (5%) off-label at UK or EU pharmacies?

6 upvotes 3 months ago

The conversation is about hair loss treatments, specifically discussing Clascoterone (5%) availability in UK or EU pharmacies. Users also mention pyrilutamide and its availability from Kintor as a cosmetic.

View more "kintor pharma" in community →

Learn

2 / 801 results

learn KX-826

Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.

learn Pyrilutamide

highly targeted anti-androgen that might have minimal systemic effects

View more "kintor pharma" in learn →

Research

5 / 449 results

Development and Validation of Androgen-Induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents

research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents

1 citations , April 2024 in “Journal of Pharmaceutical and Pharmacological Sciences”

This study evaluated androgen-induced hair loss and anagen induction mouse models, finding that Minoxidil and Pyrilutamide significantly promoted hair growth by decreasing androgen receptor protein levels and enhancing the Wnt/β-Catenin signaling pathway, supporting their use in studying novel treatments for androgenetic alopecia.

research Comparison of the pharmacoeconomic profiles of treatment regimens for field pattern actinic keratoses

April 2016 in “Journal of The American Academy of Dermatology”

In this study, exposure to ARBs, ACE inhibitors, and thiazides was associated with an increased risk of various skin cancers, including melanoma and nonmelanoma types, highlighting potential clinical implications for antihypertensive treatment choices.

research Dermatology

1 citations , February 2004

This chapter discusses various skin diseases and the adaptation of clinical trial methods to different dermatological conditions, without providing new research findings.

research Folliculitis Keloidalis Nuchae and Pseudofolliculitis Barbae

49 citations , March 2014 in “Dermatologic clinics”

This article discusses the causes, development, treatment, and prevention strategies for pseudofolliculitis barbae and folliculitis keloidalis nuchae, but reports no new clinical results.

research Pharmacological therapeutics in androgenetic alopecia

3 citations , May 2020 in “Journal of The Korean Medical Association”

This review discusses treatment options for androgenetic alopecia, with a focus on the better efficacy of oral finasteride and dutasteride over topical minoxidil for male pattern hair loss, but it reports no new clinical results.

View more "kintor pharma" in research →

Clinics

6 / 21 results

All 21 clinic results →

Experts

— no results

Try a deeper search in experts →